^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FGFR2 (Fibroblast growth factor receptor 2)

    i
    Other names: FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor 2
    2d
    Proteogenomic profiling of soft tissue leiomyosarcoma reveals distinct molecular subtypes with divergent outcomes and therapeutic vulnerabilities. (PubMed, bioRxiv)
    Immune profiling shows P2 as immunosuppressive, characterized by LGALS9 and M2 macrophages. Our proteogenomic analyses provide a molecular landscape of LMS, revealing biological insights, patient outcome stratification, and therapeutic targets.
    Journal • PARP Biomarker
    |
    FGFR2 (Fibroblast growth factor receptor 2) • HRD (Homologous Recombination Deficiency) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • IGF1R (Insulin-like growth factor 1 receptor) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • AURKA (Aurora kinase A) • NCOR1 (Nuclear Receptor Corepressor 1) • LGALS9 (Galectin 9)
    |
    HRD
    3d
    Clinicopathologic and prognostic significance of TIAM2 overexpression in resected hepatocellular carcinoma. (PubMed, Future Sci OA)
    Some known tumor-related genes, such as FGD6, FGFR2 and FZD1, were strongly related to TIAM2 gene. TIAM2 overexpression closely correlated with tumor multiplicity and poor prognosis in resected HCC, thus being a potential therapeutic target.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 mutation
    4d
    The Value of Detecting and Monitoring ctDNA in Uveal Melanoma: Results of a Pilot Study and a Systematic Review. (PubMed, Case Rep Ophthalmol)
    Co-occurrence of GNAQ, GNAS, and IDH1 mutations may represent a molecular signature of recurrence. Further validation in larger cohorts is needed to define optimal gene panels and VAF thresholds for clinical use.
    Journal • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • STK11 (Serine/threonine kinase 11) • GNAQ (G Protein Subunit Alpha Q) • BAP1 (BRCA1 Associated Protein 1) • GNAS (GNAS Complex Locus)
    |
    IDH1 mutation
    |
    Ion AmpliSeq™ Cancer Hotspot Panel v2
    5d
    RAD51B-EZH2 axis as a potential therapeutic target for TNBC through cell fate conversion. (PubMed, Cell Death Dis)
    Inhibition of the RAD51B-EZH2 axis allows the re-expression of functional ERα, making TNBC targetable by endocrine therapy. Consistently, the combination of EZH2 inhibitor with tamoxifen effectively reduces TNBC progression, suggesting that the RAD51B-EZH2 axis is a potential therapeutic target for TNBC.
    Journal • BRCA Biomarker
    |
    ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • RAD51B (RAD51 Paralog B)
    |
    FGFR2 mutation
    |
    tamoxifen
    5d
    HIF-1α silencing downregulates SLC37A2, SLC37A3, and G6PC3 gene expression and impacts glioblastoma stemness features in 3D neurospheres. (PubMed, Biochem Biophys Res Commun)
    Our findings suggest that GBM-derived 3D neurosphere cultures exhibit HIF-1α-regulated molecular features consistent with CSC and a potential mimicry of chemoresistance-associated traits rather than a direct demonstration of chemoresistance. These correlative observations support a potential link between metabolic reprogramming and the emergence of such phenotypes in response to hypoxic stress. Further investigation is needed to establish causal relationships and to better understand the underlying mechanisms.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • PTCH1 (Patched 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • GATA3 (GATA binding protein 3) • PROM1 (Prominin 1) • SLC2A1 (Solute Carrier Family 2 Member 1)
    6d
    MET signaling drives acquired resistance to erdafitinib in muscle-invasive bladder cancer cells. (PubMed, Cell Death Dis)
    Combined inhibition of FGFR1 and MET significantly suppressed tumor growth in resistant cells. These findings establish MET amplification and GAB1-SHP2 signaling as central mediators of erdafitinib resistance in FGFR1-amplified MIBC and support dual FGFR1/MET targeting as a promising therapeutic strategy.
    Preclinical • Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • HGF (Hepatocyte growth factor) • GAB1 (GRB2 Associated Binding Protein 1)
    |
    MET amplification
    |
    Balversa (erdafitinib)
    8d
    The Role of FGFR2 as a Novel Biomarker for Treatment of Gastric Cancer-A Literature Review. (PubMed, Medicina (Kaunas))
    FGFR2 represents a promising biomarker and therapeutic target in gastric cancer.
    Review • Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    8d
    Circulating Tumor DNA (ctDNA) in Gastroesophageal Adenocarcinoma (GEA): Evidence and Emerging Applications. (PubMed, Cancers (Basel))
    Ongoing trials are testing MRD-guided escalation/de-escalation and ctDNA-directed biomarker therapy. In this review, we evaluate the role of ctDNA in GEA cancers over recent years.
    Review • Journal • MSi-H Biomarker • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2)
    |
    MSI-H/dMMR
    9d
    Association between FGFR2b Positivity and Survival Outcomes of Patients with Gastric Cancer Treated with First-Line Nivolumab Plus Chemotherapy. (PubMed, Cancer Res Treat)
    FGFR2b expression exhibits substantial intratumoral heterogeneity in gastric cancer and may be linked to favorable outcomes in patients undergoing first-line ICI plus chemotherapy. Therefore, future studies should validate this finding, along with mechanistic investigations.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 overexpression
    |
    Opdivo (nivolumab)
    10d
    Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patients. (PubMed, NPJ Precis Oncol)
    Four clinical examples illustrated LB-guided therapies. This largest-to-date aSCC cohort reinforces molecular profiling-especially LB-as a key tool for guiding personalized therapy.
    Journal • Liquid biopsy • Tumor mutational burden • BRCA Biomarker
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • KMT2D (Lysine Methyltransferase 2D) • FBXW7 (F-Box And WD Repeat Domain Containing 7)
    |
    TP53 mutation • EGFR mutation • TMB-H • BRAF mutation • NRAS mutation • PIK3CA mutation • PTEN mutation • FGFR2 mutation
    |
    FoundationOne® CDx • FoundationOne® Liquid CDx
    11d
    De Novo Design of Peptide Masks Enables Rapid Generation of Conditionally-Active Miniprotein Binders. (PubMed, J Am Chem Soc)
    Additionally, by chemically conjugating a photocleavable linker, we created a light-responsive version of the masked binder, enabling external control with comparable efficiency to protease-sensitive designs. This work establishes a generalizable, rapid, and efficient platform for designing cleavable peptide masks from scratch, paving the way for conditionally active protein therapeutics responsive to endogenous or exogenous stimuli.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • FGFR2 (Fibroblast growth factor receptor 2) • IL7R (Interleukin 7 Receptor)
    11d
    Precision medicine advances in pancreatic cancer driven by genomic and molecular alterations. (PubMed, World J Gastrointest Oncol)
    Cross-cancer analyses underscore the necessity of PDAC-specific strategies despite shared genomic drivers. Collectively, these insights support routine germline and somatic testing, enrollment in biomarker-matched trials, and rational combination strategies, establishing molecular profiling as central to advancing precision treatment in pancreatic cancer.
    Review • Journal • Tumor mutational burden • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • RET (Ret Proto-Oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • SMAD4 (SMAD family member 4)
    |
    TP53 mutation • TMB-H • BRAF V600 • RET fusion • FGFR2 fusion